To evaluate the impact of a combined treatment of angiotensin II type 1 (AT 1 )-receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition (statin) on the secretory phospholipase A 2 type IIA (sPLA 2 -IIA) and oxidized low density lipoprotein (oxLDL) in patients with coronary artery disease (CAD).
Introduction
Atherosclerosis with its associated cardiovascular eventsmyocardial infarction, sudden cardiac death, or stroke-is one of the leading causes of death in the western countries. 1 Both, chronic activation of the renin-angiotensin system (RAS) and lipoproteins, especially oxidatively modified low density lipoproteins (oxLDLs) are well-established contributors to the development and progression of atherosclerosis. Interestingly, RAS activation as a characteristic feature of the hypertensive cardiovascular system and enhanced LDL levels are often co-existent and may worsen the prognosis of the patients affected. 2 -4 Besides a sole co-existence, direct interactions between a chronically activated RAS and lipoproteins have been indicated, which may further promote atherogenesis. This concurrence may be procured via angiotensin (Ang) II, the effector peptide of the RAS and activation of the angiotensin II type 1 (AT 1 )-receptor. 5 Thus, it is not surprising, that some experimental as well as clinical evidence support the notion that the combination of 3-hydroxy-3-methyl-glutaryl (HMG)-CoA-reductase inhibition (statin) with an AT 1 -receptor antagonist may act additively. 6 -9,10 However, the underlying mechanisms as well as the clinical impact of such an adjunction remain a matter of ongoing debate. In this regard, recent findings by our group indicated that Ang II-mediated LDL oxidation seemingly depends on the expression and activity of the secretory phospholipase type IIA (sPLA 2 -IIA), an acute-phase reactant and independent predictor for coronary events in healthy subjects and patients with documented coronary artery disease (CAD).
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SPLA 2 -IIA hydrolyses cell membrane phospholipids, leading to the formation of free fatty acids and lysophospholipids which are precursors of pro-inflammatory prostaglandins, leukotrienes, and platelet-activation factor. These factors enhance lipid aggregation and LDL oxidation and stimulate oxLDL uptake by macrophages, important aspects of atherosclerotic plaque development. 14 -16 In the circulation, sPLA 2 directly hydrolyses LDL which leads to the formation of oxidation-susceptible, small-dense LDL particles with altered configuration of apolipoprotein B, resulting in an LDL-receptor-independent cellular uptake of lipoproteins. Interestingly, histological studies of human atherosclerotic plaques revealed a positive correlation between sPLA 2 -IIA expression and disease severity. 17 Furthermore, sPLA 2 -IIA was associated with an increased risk for restenosis after percutaneous transluminal coronary angioplasty. 18 On the basis of this evidence, we hypothesized that sPLA 2 -IIA-by mediating Ang II-dependent LDL oxidation-might be involved in the interactions between RAS activation and hypercholesterolaemia and therefore represent an attractive new target in the treatment of patients with CAD. Thus, we investigated whether an AT 1 -receptor blockade on top of a standard statin treatment elicits additional effects on circulating sPLA 2 -IIA and oxLDL in patients with established CAD. patients who received a drug-eluting stent were also excluded. The patients were asked to give their written informed consent to participate after PCI. Among 237 patients listed for PCI, finally 62 patients left to be enrolled in the present study 6 weeks after PCI following a computer-generated randomization list. All patients had angiographically documented CAD without residual flow-limiting coronary stenosis (no coronary stenosis .50%) after the performed PCI, an ejection fraction 55% and normal exercise stress test prior to randomization as required safety parameter. None of the patients reported symptoms of angina pectoris or heart failure at the time of inclusion into the study. The patients' screening and inclusion procedure as well as patients' follow-up is shown in Figure 1 . The study was approved by the local Ethics Committee (#3059/ 2003) and all patients gave their written informed consent to participate.
Methods Patients

Study objectives and study protocol
The current study was aimed to investigate whether an AT 1 -receptor blockade on top of a standard statin treatment elicits additional effects on circulating sPLA 2 -IIA and subsequently on lipid-peroxidation products such as oxLDL and established markers of inflammation such as high-sensitivity (hs)-C-reactive protein in patients with established CAD.
We defined one primary endpoint (baseline adjusted treatment effect of between-group comparisons for lowering sPLA 2 activity after 3 months) and six secondary endpoints (treatment effects for lowering blood pressure and sPLA2-protein, oxLDL, LDL HDL, and hs-C-reactive protein concentrations).
Patients were randomly assigned in a 1:1 ratio to receive either pravastatin (n ¼ 32 patients, 40 mg/day, group A, PRAV) or pravastatin plus irbesartan (n ¼ 30, 40 mg/day pravastatin and 300 mg/day irbesartan, group B, IRBþPRAV) in a double-blinded fashion following sequentially a randomization list without using blocks or stratifications. The study drug was blinded by the hospital pharmacy. All study personnel and patients were blinded to treatment assignment. There were identical sequentially numbered boxes (after unblinding¼group A, pravastatinþplacebo, and ¼group B, pravstatinþirbesartan); each box containing two bottles labelled as 'medication A' (after unblinding¼pravastatin) and 'medication B' (after unblinding¼either irbesartan or placebo). 'Medication B' was uptitrated after 2 weeks. Accordingly, patients received irbesartan at the starting dose of 150 mg and were uptitrated to 300 mg after 2 weeks. Pravastatin was administered at the dosage of 40 mg/day during the entire study. Both treatments were administered for 3 months. The groups were unblinded at the end of the entire study. (Figure 2 ). As shown in Figure 1 , two patients (after unblinding each from the PRAV group) dropped out 2 and 9 days after starting study medication without giving a reason. We did not include these two patients in our analysis because this might potentially alter baseline levels but parameters at 3 months would not change with regard to the final outcome based on the fact that they factually did not have really started the study.
Blood sampling and laboratory analysis
Serum samples were collected at baseline and after 3 months. Blood samples were drawn in a seated position from the antecubital vein and serum samples were stored at 2808C before use. Serum sPLA 2 -IIA protein and sPLA 2 activity, hs-C-reactive protein and oxLDL were measured at baseline and at 3 months of follow-up using an enzyme-linked immunabsorbent assay (ELISA) technique. Non-invasive blood pressure measurement was performed in seated position by Riva-Rocci/Korotkow's method.
Combined treatment of AT 1 -receptor blockade and HMG-CoA-reductase in CAD patients Study personnel and patients were blinded to the results of the laboratory analysis performed at the end of the entire study. Only the study data monitoring personnel saw unblinded data with regard to safety parameters but none had any contact with the patients.
High-sensitivity-C-reactive protein analysis
Plasma samples obtained at baseline and at 3 months were thawed and assayed for hs-C-reactive protein using a high-sensitivity enzyme immunoassay with a coefficient of variation below 5% (Dade Behring using a BN II nephelometer analyzer, FDA-approved). The limits of detection (0.02 mg/L) and quantification (0.15 mg/L) were reported recently. 12 Every experiment was performed in triplicates. Data are given as mean + SEM.
Secretory phospholipase A2 type-IIA assays
Plasma samples obtained at baseline and at 3 months were thawed. SPLA 2 -IIA ELISA (Cayman Chemical Company, Ann Arbor, MI, USA) was performed to determine the protein concentration in serum samples and sPLA 2 activity was assessed in serum samples by a commercially available kit (Quantikine R&D Systems, Minneapolis, Minnesota) following the recommendations of the manufacturer.
Every experiment was performed in triplicates (Fluostar Galaxy, BMG Lab technologies) and the results are given as mean + SEM. Intra-assay variability from triplicate analysis was below 1% in all samples.
Determination of oxidized low density lipoprotein
OxLDL were determined in EDTA-plasma of patients by ELISA technique (Mercodia) utilizing a specific murine monoclonal antibody mAb-4E6. 19 OxLDL ELISA was performed following manufacturer's recommendations; each measurement was performed in triplicates (Fluostar Galaxy, BMG Lab technologies).
Statistical analysis
All statistical analyses were performed by the Department of Biometrics. The primary endpoint was the baseline-adjusted treatment effect of between-group comparisons for lowering sPLA2-activity after 3 months. Secondary endpoints were defined as baseline-adjusted between-group treatment effects for lowering blood pressure and sPLA2 protein, oxLDL, LDL, HDL, and hs-C-reactive protein levels. Data were analysed by ANCOVA using the SAS procedure MIXED. Figure 1 Patients' screening, inclusion procedure, and follow-up. Sixty-two patients with coronary artery disease and a history of arterial hypertension were identified among 237 patients listed for elective percutaneous coronary intervention and enrolled in the present study 6 weeks after percutaneous coronary intervention following a computer-generated randomization list.
All tests were performed two-sided and P , 0.05 were considered as statistically significant. Sample size was calculated for an independent t-test of the means post-therapy with a ¼ 0.05. With a sample size of 27 per group, a relative effect of 80% of the standard deviation is detectable with a power of 80%. Thus, with an a priori estimated standard deviation of 35 U/mL, a difference of about 28 U/mL is detectable for the primary endpoint sPLA2 activity which we consider as clinical relevant.
Results
Clinical characteristics
Both PRAV-and PRAVþIRB-treated groups did not differ with regard to gender, body mass index, cardiovascular risk factor profile, or medication ( Table 1) . Four patients in the PRAVþIRB group and two patients in the PRAV group received oral antidiabetic medication for non-insulin-dependent diabetes. No patient received AT 1 -receptor antagonists, ACE-inhibitors, or statins prior to inclusion into the study. Patients with CAD and a history of arterial hypertension received standard treatment with 100 mg of acetyl salicylic acid, as well as anti-hypertensive treatment with beta-blockers, calcium channel antagonists, and diuretics during the 6 weeks from screening to therapy onset as summarized in Table 1 . None of the patients reported symptoms of angina pectoris or heart failure at the time of randomization as well as during the 3 months of follow-up. At baseline and after 3 months of treatment, no differences with regard to safety parameters i.e. serum electrolytes, renal function, Figure 2 Study design. Patients were treated in a double-blinded fashion 6 weeks after elective percutaneous coronary intervention. One group received a statin treatment with pravastatin (40 mg/day) and the other group received the combination of pravastatin and the angiotensin II type 1-receptor antagonist irbesartan (300 mg/day). After 3 months, secretory phospholipase A 2 -type IIA activity (primary endpoint), secretory phospholipase A 2 protein, blood pressure, low-density lipoprotein and high density lipoprotein cholesterol, high-sensitivity-C-reactive protein, and oxidized low density lipoprotein levels were determined. 
Impact on high-sensitivity-C-reactive protein
Baseline levels did not differ between the groups with a trend towards numerically higher levels in the PRAVþIRB group (P ¼ 0.0568). Impact on secretory phospholipase A2 type IIA activity, secretory phospholipase A2 type IIA protein, and oxidized low density lipoprotein Baseline levels of, sPLA 2 activity, sPLA 2 protein, and oxLDL were not significantly different.
The combined treatment with PRAVþIRB resulted in a reduction in circulating levels of sPLA 2 activity (IRBþPRAV 73.03 + 11.6 to 60.01 + 8.6 U/mL vs. PRAV 82.44 + 7.7. to 87.64 + 9.3 U/mL) and sPLA 2 protein (IRBþPRAV 4720 + 1096 to 3524 + 725 pg/ mL vs. PRAV 5009 + 1168 to 5555 + 1480 pg/mL). There was a significant reduction in the primary endpoint sPLA 2 activity [baseline-adjusted treatment effect of between-group comparison: 22.88 U/mL (95% CI 7.23; 38.53); P ¼ 0.0049] (Figure 4 ) and in a significant but not so pronounced reduction in sPLA 2 protein [1793.82 pg/mL (95% CI 322.87; 3264.74); P ¼ 0.0177] ( Figure 5) .
There was also a reduction in oxLDL levels in the PRAVþIRB group (IRBþPRAV 60.18 + 2.9 to 47.06 + 1.9 U/L), whereas oxLDL levels determined in the PRAV treatment group remained nearly unchanged (PRAV 79.01 + 7.7 to 78.04 + 8.2 U/L). The effect in the PRAVþIRB group on oxLDL serum levels was alsosignificantly more profound when compared with PRAV treatment alone [baseline-adjusted treatment effect of between-group comparison 162.55 U/L (95% CI 45.15; 279.95); P ¼ 0.0075] ( Figure 6) . Moreover, the effect on oxLDL was independent of changes in LDL cholesterol. In fact, the combined treatment decreased the oxidized LDL-to-LDL-cholesterol ratio (50.8 + 18.9 U/mg to 49.4 + 19.6 U/mg). Thus, the impact on oxidized LDL-to-LDL-cholesterol ratio changes was significantly more pronounced in the PRAVþIRB group Raw data for blood pressure and laboratory parameters at baseline and after 3 months of therapy are presented in Table 2 .
The estimated baseline-adjusted treatment effect obtained by ANCOVA and the 95% CI of the differences between the two groups for the primary and secondary endpoints after 3 months of therapy are summarized in Table 3 .
Discussion
Here we report that only the adjunction of pravastatin and irbesartan reduced sPLA 2 -IIA activity, sPLA 2 -IIA protein concentration, and oxLDL levels in patients with CAD. Oxidative modifications of lipoproteins are considered as pivotal contributors to atherosclerotic plaque development and both sPLA 2 -IIA and Ang II via its AT 1 -receptor are involved in LDL peroxidation. 20 In fact, modifications of LDL mediated by sPLA 2 isoenzymes result in enhanced oxLDL uptake by macrophages and increased LDL affinity for proteoglycans, a critical step for LDL diffusion and deposition in the vessel wall. 14,21 -23 Recent experimental data further demonstrated a cross-talk between cytosolic phospholipase A 2 (cPLA 2 ) and sPLA 2 -IIA with regard to free radical release suggesting an additional mechanism through which sPLA 2 -IIA may enhance oxidative LDL modification. 24 Early evidence for a potential role of Ang II in LDL oxidation was gathered by Keidar et al. 25, 26 who reported an increased propensity of LDL obtained from hypertensive patients to oxidative modification in comparison with LDL from normotensive subjects. Meanwhile, various interactions between Ang II and oxLDL have been demonstrated, including increased affinity of oxLDL to its scavenger receptor, enhanced oxLDL uptake by macrophages, and elevated intracellular lipid peroxidation in different animal models of atherosclerosis as well as in human vascular cells. 27 -30 A possible interaction between an activated RAS and phospholipases has been indicated by observations showing that inhibitors of phospholipase A 2 , C, and D substantially decrease Ang II-induced macrophage lipid peroxidation. 27 In fact, our group recently reported that Ang II-dependent LDL oxidation may effectively be reduced by a specific inhibitor of active sPLA 2 -IIA. Moreover, treatment with the AT 1 -receptor antagonist irbesartan alone decreased sPLA 2 -IIA expression and sPLA 2 -activity in vitro and in vivo in a small population of patients with documented CAD. 13 Thus, Ang II-induced AT 1 -receptor activation may enhance oxidative LDL modifications via sPLA 2 -IIA and thereby facilitate atheroprogression ( Figure 7) . Based on these findings, we investigated the potential impact of a combined treatment with pravastatin and irbesartan on sPLA 2 -IIA and oxLDL in patients with CAD. We postulated that the addition of an AT 1 -receptor antagonist to the standard secondary prevention therapy with a statin might exert additional effects on sPLA 2 -IIA and LDL oxidation. We here report, that both treatment regimens comparably influenced blood pressure, LDL-cholesterol levels, and the acutephase reactant hs-C-reactive protein. Interestingly, sPLA 2 activity was intensively reduced in patients treated with the adjunction of pravastatin and irbesartan with a significant but not so pronounced reduction in sPLA 2 protein. This is consistent with the observation of Mallat et al. 31 that whole sPLA2 activity may have a better prognostic value than the sPLA 2 -protein level in patients Combined treatment of AT 1 -receptor blockade and HMG-CoA-reductase in CAD patients with CAD. In fact, pravastatin alone tended to result in numerically enhanced circulating sPLA 2 -IIA protein and activity which could be related to interferon-g-dependent signalling events. 32 On the basis of our previous findings, which suggested sPLA 2 -IIA as a mediator of Ang II-dependent LDL oxidation, we also investigated the impact of both treatment regimens on oxLDL levels. Surprisingly, only the combination of pravastatin with irbesartan reduced this parameter, independent of changes in LDL cholesterol, whereas treatment with pravastation alone did not influence oxLDL levels. These results are contrary to the findings of other groups, even though similar dosages were used. 33, 34 These diverging observations could be due to the fact that the impact of pravastatin on oxLDL levels in patients with CAD has not been investigated yet. In addition, the relatively short treatment period used in this study as well as only moderately increased oxLDL levels may have influenced the results obtained. 33, 35 Moreover, we cannot fully exclude that by using another statin a different effect on oxLDL could have been observed, although a recent review by Boehm et al. 36 stated that statins have not been proven to possess differential potencies (regarding their ability to reduce cardiovascular events) if they are used in a dosage which results in similar LDL reductions. In this regard, the dosage used in the study presented is in line with the dosage used in large-scale clinical trials demonstrating the effectiveness of 40 mg/day pravastatin in the primary and secondary prevention of cardiovascular events.
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Study limitations
Even though our observation is in line and consistent with previous experimental and pre-clinical reports, one of our limitations is the rather small number of patients at low risk. Therefore, larger double-blind, placebo-controlled trials are warranted in order to Combined treatment of AT 1 -receptor blockade and HMG-CoA-reductase in CAD patients confirm our findings. In addition, even though it would be helpful to have a study arm without statin treatment, it is nowadays recommended in the guidelines for patients with CAD undergoing PCI to use statin treatment. Thus, we did not include a treatment group with AT 1 -receptor blockade alone. Such a group, however, would have helped us to clarify the individual impact of irbesartan on the parameters investigated under clinical conditions, even though our previous experimental work provided molecular insight into the potential underlying mechanism. Finally, we cannot exclude an influence of some imbalance at baseline values because of our two patient dropouts in the PRAV group.
Summary
To summarize, we here demonstrate that only the combined treatment of irbesartan with pravastatin decreases the circulating levels of the cardiovascular prognostic marker sPLA 2 -IIA and of oxLDL in patients with CAD. This impact may, at least partially, be explained by the specific blockade of AT 1 -receptor-dependent sPLA 2 -IIA expression and activation, which results in the inhibition of sPLA 2 -IIA-induced LDL oxidation ( Figure 7) . Figure 7 Proposed mechanism for the impact of angiotensin II type 1-receptor blockade and statin treatment on secretory phospholipase A 2 -IIA and oxidized low density lipoprotein. Angiotensin II type 1-receptor blockade results in decreased formation and activation of secretory phospholipase A 2 -IIA. This decrease inhibits secretory phospholipase A 2 -IIA-dependent formation of leukotrienes and prostaglandins, resulting in less generation of reactive oxygen species and subsequently less oxidation of low density lipoprotein. Statin treatment directly reduces low density lipoprotein levels and oxidized low density lipoprotein formation. Thus, by targeting oxidized low density lipoprotein generation through different molecular mechanisms, angiotensin II type 1-receptor blockade and statin treatment may additionally influence atherosclerotic disease progression and, possibly, cardiovascular events.
